Mosaic Family Wealth Partners LLC Buys 6,774 Shares of AbbVie Inc. $ABBV

Mosaic Family Wealth Partners LLC grew its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 108.2% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,033 shares of the company's stock after buying an additional 6,774 shares during the period. Mosaic Family Wealth Partners LLC's holdings in AbbVie were worth $3,280,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Litman Gregory Wealth Management LLC purchased a new position in AbbVie during the fourth quarter valued at approximately $28,000. Imprint Wealth LLC boosted its position in shares of AbbVie by 56.2% in the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company's stock worth $29,000 after purchasing an additional 45 shares during the period. IFC & Insurance Marketing Inc. purchased a new stake in shares of AbbVie in the fourth quarter worth $31,000. Legacy Wealth Managment LLC ID raised its position in shares of AbbVie by 115.9% during the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company's stock valued at $31,000 after purchasing an additional 73 shares during the period. Finally, Marquette Asset Management LLC raised its position in shares of AbbVie by 52.2% during the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company's stock valued at $35,000 after purchasing an additional 48 shares during the period. 70.23% of the stock is currently owned by institutional investors.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $264.61 on Tuesday. The firm has a fifty day moving average price of $249.34 and a 200 day moving average price of $227.78. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $267.47. The firm has a market cap of $467.52 billion, a price-to-earnings ratio of 74.75, a P/E/G ratio of 0.88 and a beta of 0.30.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. AbbVie's revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, research analysts predict that AbbVie Inc. will post 14.06 earnings per share for the current year.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie's payout ratio is 195.48%.

Insider Activity

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the business's stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.06% of the company's stock.

Analyst Ratings Changes

A number of research firms recently weighed in on ABBV. Canaccord Genuity Group lifted their target price on shares of AbbVie from $282.00 to $290.00 and gave the company a "buy" rating in a research note on Monday, August 3rd. Weiss Ratings raised AbbVie from a "hold (c)" rating to a "buy (b-)" rating in a report on Tuesday, August 4th. Barclays raised their price target on AbbVie from $275.00 to $300.00 and gave the company an "overweight" rating in a report on Wednesday, July 29th. Citigroup upped their price objective on AbbVie from $230.00 to $260.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 15th. Finally, Wall Street Zen cut AbbVie from a "strong-buy" rating to a "buy" rating in a research report on Sunday, July 5th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, AbbVie currently has an average rating of "Moderate Buy" and a consensus price target of $275.95.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source